© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Victrelis or Incivek-based triple therapy for hepatitis C virus resulted in low cure rates and high rates of serious side effects among those...
Treating hepatitis C post-liver transplant yields moderately good results with Victrelis (boceprevir) or Incivek (telaprevir)-based triple the...
Faldaprevir with pegylated interferon and ribavirin cured about 80 percent of treatment-naive people with genotype 1 of hepatitis C in a Phase...
The HIV antiretrovirals Viread (tenofovir) and Emtriva (emtricitabine), can suppress hepatitis B in three-quarters of those with ?immune-toler...
A Phase III trial sofosbuvir and ribavirin cured 90 percent of those with genotypes 1, 4, 5 and 6 of hepatitis C.
Sofosbuvir and daclatasvir, taken with or without ribavirin, cured 100 percent of previously treated participants of hepatitis C virus in...
Sofosbuvir and ribavirin cured participants with genotype 2 or 3 of hepatitis C virus at rates in the mid-70 percent range in two new Phase II...
AbbVie?s five-drug hepatitis C virus (HCV) combination therapy demonstrated cure rates in the mid-90 percent range when taken for as little as...
Hepatitis C therapy including daclatasvir, asunaprevir and BMS-791325 achieved a cure in up to 94 percent of treatment-naive people with genot...
The investigational NS3/4A protease inhibitor simeprevir cured four out of five people with genotype 1 of hepatitis C and compensated liver di...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.